x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

1,530
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS

Métricas

  • Factor de Impacto: 1,530(2015)
  • 5-años Factor de Impacto: 1,710
  • SCImago Journal Rank (SJR):0,43
  • Source Normalized Impact per Paper (SNIP):0,653
doi: 10.1016/S0213-005X(03)72893-6
Aminoglucósidos
Aminoglycosides
Julián Pualomino1, , Jerónimo Pachón
Servicio de Enfermedades Infecciosas. Hospital Universitario Virgen del Rocío. Sevilla. España
Recibido 03 diciembre 2002, Aceptado 04 diciembre 2002
Resumen

Los aminoglucósidos permanecen como una clase de antimicrobianos de uso habitual y eficaz en la práctica clínica. A pesar de que existen diversos mecanismos de resistencia continúan siendo activos frente a gran parte de los bacilos gramnegativos aerobios. En la actualidad, aunque pueden utilizarse en monoterapia en las infecciones urinarias, se utilizan fundamentalmente en combinación con betalactámicos en infecciones graves por bacilos gramnegativos. Los conocimientos sobre los parámetros farmacocinéticos y farmacodinámicos han sugerido su uso en monodosis, cuya eficacia ha sido similar a la administración en multidosis en diversos estudios, los cuales también han demostrado una tendencia a menor toxicidad. Entre los efectos adversos, la nefrotoxicidad y la ototoxicidad requieren una vigilancia cuidadosa durante su administración.

Resumen

Aminoglycosides remain as a efficacious class of antimicrobials, commonly used in the clinical practice. In spite of the existence of several mechanisms of resistance, they continue being active against most of the aerobic Gram-negative bacilli. Currently, although aminoglycosides may be used as monotherapy in the urinary tract infections, they are mainly used in combination with β-lactam antibiotics in severe infections caused by Gram-negative bacilli. The knowledge about the pharmacokinetic and pharmacodynamic parameters of aminoglycosides has suggested their use in an once-daily dosing regimen. This dosing has shown as efficacious as multiple-daily dosing regimen in several studies, which also have shown a trend toward a lower toxicity. Among the adverse events, nephrotoxicity and ototoxicity require a careful evaluation during its administration.

Palabras clave
Aminoglucósidos, Monodosis, Tratamiento antimicrobiano
Key words
Aminoglycosides, Once-daily dosing, Antimicrobial treatment
El Texto completo solo esta disponible en PDF
Bibliografía
1.
S.J. Pancoast
Aminoglycoside antibiotics in clinical use
Med Clin North Am, 72 (1988), pp. 581-612
2.
M.P. Mingeot-Leclercq,Y. Glupczynski,P.M. Tulkens
Aminoglycosides: Activity and resistance
Antimicrob Agents Chemother, 43 (1999), pp. 727-737
3.
M.K. Lacy,D.P. Nicolau,C.H. Nightingale,R. Quintiliani
The pharmacodynamics of aminoglycosides
Clin Infect Dis, 27 (1998), pp. 23-27
4.
W.A. Craig
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
Clin Infect Dis, 26 (1998), pp. 1-12
5.
D.N. Gilbert
Aminoglycosides
5th ed, pp. 307-336
6.
R.S. Edson,C.L. Terrell
The aminoglycosides
Mayo Clinic Proc, 74 (1999), pp. 519-528
7.
C.D. Freeman,D.P. Nicolau,P.P. Belliveau,C.H. Nightingale
Once-daily dosing of aminoglycosides: Review and recomendations for clinical practice
J Antimicrob Chemother, 39 (1997), pp. 677-686
8.
A.W. Urban,W.A. Craig
Daily dosage of aminoglycosides
Curr Clin Top Infect Dis, 17 (1999), pp. 236-255
9.
D.N. Fisman,K.M. Kaye
Once-daily dosing of aminoglycoside antibiotics
Infect Dis Clin North Am, 14 (2000), pp. 475-487
10.
J. Blaser,B.B. Stone,M.C. Groner,S.H. Zinner
Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
Antimicrob Agents Chemother, 31 (1987), pp. 1054-1060
11.
G.M. Eliopoulos,R.C. Moellering
Antimicrobial combinations
4th ed, pp. 330-383
12.
National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. Document M100-S11.Wayne: National Committee for Clinical Laboratory Standards, 2001
13.
Recomendaciones del grupo mensura
para la selección de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del antibiograma
Rev Esp Quimioterap, 13 (2000), pp. 73-86
14.
F.J. Schmitz,J. Verhoef,A.C. Fluit,the SENTRY Participants Group
Prevalence of aminoglycoside resistance in 20 european university hospitals participating in the european sentry antimicrobial surveillance programme
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 414-421
15.
C. Betriu,L. Palau,M. Gómez,A. Sánchez,J. Romero,J.J. Picazo
Bacteriemias en un hospital universitario: estudio de los agentes etiológicos y de sus patrones de sensibilidad
Rev Clin Esp, 199 (1999), pp. 503-510
16.
F. Fernández-Cuenca,A. Pascual,J. Vila,G. Bou,J.M. Cisneros,J. Rodríguez Baño
Proyecto Geih-Ab 2001: Sensibilidad de Acinetobacter spp. aislados en hospitales españoles a los antimicrobianos
X Congreso de laSociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Sevilla, 17-20 de marzo de 2002. Enferm Infecc Microbiol Clin, 20 (Suppl 1) (2002), pp. 122
17.
G.H. Miller,F.J. Sabatelli,R.S. Hare,H.Y. Glupczynski,P. Mackey,D. Shales
The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: A reflection of aminoglycoside usage patterns?Clin Infect Dis, 24 (Suppl 1) (1997), pp. S46-S62
18.
J.C. Graham,F.K. Gould
Role of aminoglycosides in the treatment of bacterial endocarditis
Antimicrob Chemother, 49 (2002), pp. 437-444
19.
M. Hilf,L. Yu,J. Sharp,J.J. Zuravleff,J.A. Korvick,R.R. Muder
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients
Am J Med, 87 (1989), pp. 540-546
20.
J.W. Chow,M.J. Fine,D.M. Shlaes,J.P. Quinn,D.C. Hooper,M.P. Johnson
Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy
Ann Intern Med, 115 (1991), pp. 585-590
21.
J.A. Korvick,C.S. Bryan,B. Farber,T.R.Jr. Beam,L. Schenfeld,R.R. Muder
Prospective observational study of Klebsiella bacteremia in 230 patients:Outcome for antibiotic combinations versus monotherapy
Antimicrob Agents Chemother, 36 (1992), pp. 2639-2644
22.
L. Liebovici,M. Paul,O. Poznanski,M. Drucker,Z. Samra,H. Konigsberger
Monotherapy versus β-lactam-aminoglycoside combination treatment forgram-negative bacteremia: a prospective, observational study
Antimicrob Agents Chemother, 41 (1997), pp. 1127-1133
23.
E. Bouza,P. Muñoz
Monotherapy versus combination therapy for bacterial infections
Med Clin North Am, 84 (2000), pp. 1357-1389
24.
J.P. Lynch,III
Hospital-acquired pneumonia. Risk factors, microbiology, and treatment
Chest, 119 (2001), pp. 373S-384S
25.
A.D.M. Kashuba,A.N. Nafziger,G.L. Drusano,J.S.Jr. Bertino
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
Antimicrob Agents Chemother, 43 (1999), pp. 623-629
26.
E. Rozdzinski,W.V. Kern,A. Reichle,T. Moritz,T. Schmeiser,W. Gaus
Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients
J Antimicrob Chemother, 31 (1993), pp. 585-598
27.
The international antimicrobial therapy cooperative group of the european organization for research and treatment of cancer
Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med, 119 (1993), pp. 584-593
28.
H. Ariffin,A. Arasu,M. Mahfuzah,W.A. Ariffin,L.L. Chan,H.P. Lin
Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer
J Paediatr Child Health, 37 (2001), pp. 38-43
29.
A. Favero Del,F. Menichetti,P. Martino,G. Bucaneve,A. Micozzi,G. Gentile
A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia
Clin Infect Dis, 33 (2001), pp. 1295-1301
30.
P. Van der Auwera,F. Meunier,S. Ibrahim,L. Kaufman,M.P. Derde,P.M. Tulkens
Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection
Antimicrob Agents Chemother, 35 (1991), pp. 640-647
31.
R.R. Bailey,E.J. Begg,A.H. Smith,R.A. Robson,K.L. Lynn,S.T. Chambers
Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis
Clin Nephrol, 46 (1996), pp. 183-186
32.
J.R. Carapetis,A.L. Jaquiery,J.P. Buttery,M. Starr,N.E. Cranswick,S. Kohn
Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections
Pediatr Infect Dis J, 20 (2001), pp. 240-246
33.
J.W. Warren,E. Abrutyn,J.R. Hebel,J.R. Johnson,A.J. Schaeffer,W.E. Stamm
Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women
Clin Infect Dis, 29 (1999), pp. 745-758
34.
T. Sandberg,K. Alestig,T. Eilard,E. Ek,M. Hebelka,E. Johansson
Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women
Scand J Infect Dis, 29 (1997), pp. 175-179
35.
K. Tan,H. Bunn
Once daily multiple daily dosing with intravenous aminoglycosides for cystic fibrosis
Cochrane Database Syst Rev, 4 (2000), pp. CD002009
36.
A. Whitehead,S.P. Conway,C. Etherington,N.A. Caldwell,N. Setchfield,S. Bogle
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Eur Respir J, 19 (2002), pp. 303-309
37.
R.B. Moss
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
Chest, 121 (2002), pp. 55-63
38.
X. Badía,M. Brosa,J.M. Tellado
Medicina basada en la evidencia, costes sanitarios y tratamiento de la infeccion intraabdominal
Enferm Infecc Microbiol Clin, 17(Supl 2 (1999), pp. 86-94
39.
H. Dupont,C. Carbon,J. Carlet,for The Severe Generalized Peritonitis Group
Monotherapy with broad-spectrum beta-lactam is as effective as its combination with an aminoglucoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial
Antimicrob Agents Chemother, 44 (2000), pp. 2028-2033
40.
R.G. Holzheimer,H. Dralle
Antibiotic therapy in intra-abdominal infections –a review on randomised clinical trials
Eur J Med Res, 6 (2001), pp. 277-291
41.
P.A. Gross,T.L. Barrett,E.P. Dellinger,P.J. Krause,W.J. Martone,J.E. McGowan
Purpose of quality standars for infectious diseases
Clin Infect Dis, 18 (1994), pp. 421
42.
O. Lortholary,M. Tod,Y. Cohen,O. Petitjean
Aminoglycosides
Med Clin North Am, 79 (1995), pp. 761-787
43.
D.N. Gilbert,W.M. Bennett
Use of antimicrobial agents in renal failure
Infect Dis Clin North Am, 3 (1989), pp. 517-531
44.
Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother
Correspondencia: Dr. J. Palomino. Servicio de Enfermedades Infecciosas. Hospital Universitario Virgen del Rocío. Avda. Manuel Siurot, s/n. 41013 Sevilla. España
Copyright © 2003. Elsevier España, S.L.